Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Finance Watch: Biotech Investors Take FDA Turmoil In Stride

Denali Secures $275m Royalty Deal

Dec 05 2025

• By Mandy Jackson

Finance Watch Public Company — • Source: Alamy

Related Content

Prasad Email Suggests New US FDA Vaccine Standards Coming, But More Detail Wanted

Dec 02 2025

US FDA Faces Another Leadership Crisis As Drugs Center Director Richard Pazdur Retires

Dec 02 2025

Tracy Beth Høeg Named New Acting US FDA CDER Director

Dec 04 2025

Updated: US FDA Sending Pazdur Back To Oncology Office

Dec 04 2025

Høeg Doubles Down On Prasad’s US FDA Vaccine Overhaul

Dec 05 2025

Brief Pause, Big Stakes: FDA Extends Review Of Denali’s Hunter Syndrome Therapy

Oct 14 2025

Belite Bio’s Tinlarebant  Shines In Phase III Stargardt Disease Trial

Dec 02 2025

Asia Deal Watch: Kelun And Crescent Partner And Cross-License Cancer Candidates

Dec 05 2025

Phase III Data Positions Capricor To Refile Deramiocel In Duchenne Cardiomyopathy

Dec 03 2025

Related Companies

Denali Therapeutics Inc.

Belite Bio, Inc.

Crescent Biopharma, Inc.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Capricor Therapeutics, Inc.

Immatics N.V.

Pasithea Therapeutics Corp.

Kazia Therapeutics Limited

Additional Topics

Business Strategies Policy

More from Finance Watch

More from Financing

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window